Upregulation of adrenomedullin and its receptor components during cardiomyocyte hypertrophy induced by chronic inhibition of nitric oxide synthesis in rats

Abstract

Adrenomedullin may provide a compensatory mechanism to attenuate left ventricular hypertrophy (LVH). Nitric oxide synthase inhibition, induced by chronic administration of Nω-nitro-l-arginine methyl ester (l-NAME) to rats, induces cardiac hypertrophy in some, but not all cases; there are few reports of direct assessment of cardiomyocyte parameters. The objective was to characterize hypertrophic parameters in left (LV) and right ventricular (RV) cardiomyocytes after administration of l-NAME to rats for 8 wk and to determine whether adrenomedullin and its receptor components were upregulated. After treatment with l-NAME (20 and 50 mg·kg−1·day−1), compared with nontreated animals, 1) systolic blood pressure increased (by 34.2 and 104.9 mmHg), 2) heart weight-to-body wt ratio increased 24.1% at the higher dose ( P < 0.05), 3) cardiomyocyte protein mass increased ( P = NS), 4) cardiomyocyte protein synthesis ([14C]phenylalanine incorporation) increased ( P < 0.05), 5) expression of skeletal α-actin, atrial natriuretic peptide, brain natriuretic peptide, and ET-1 mRNAs was enhanced ( P < 0.05) in LV but not RV cardiomyocytes at 20 and 50 mg·kg−1·day−1, respectively, and 6) expression of adrenomedullin, receptor activity-modifying protein 3 (RAMP3), and RAMP2 (but not calcitonin receptor-like receptor and RAMP1) mRNAs was increased by l-NAME (20 mg·kg−1·day−1) in LV. In conclusion, l-NAME enhanced protein synthesis in both LV and RV cardiomyocytes but elicited a hypertrophic phenotype accompanied by altered expression of the counterregulatory peptide adrenomedullin and receptor components (RAMP2, RAMP3) in LV only, indicating that the former is due to impaired nitric oxide synthesis, whereas the phenotypic changes are due to pressure overload.